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Carlos A. RamosTreatment of severe aplastic anemia (SAA), a rare
but life-threatening disorder, is one of the most suc-
cessful current applications of allogeneic hematopoi-
etic stem cell transplantation, with 5-year overall
survival rates exceeding 70% for adults and approach-
ing 90% for children and adolescents who receive
matched sibling grafts [1,2]. The use of unrelated
donors (URDs) has allowed extending this potentially
lifesaving procedure to a larger number of patients,
but the results reported in this setting by the Center
for International Blood and Marrow Transplant
Research are substantially worse, with survival rates
dropping almost 20% compared with those obtained
with related donors, mostly due to higher transplant-
relatedmortality, including graft failure and organ tox-
icities. Graft failure is particularly problematic in SAA
because residual recipient anti-hematopoietic immu-
nity, the underlying pathophysiology of SAA [3], may
have a detrimental effect on the graft. In addition,
many of these patientsmay be sensitized to alloantigens
as a consequence of frequent transfusional need [4], fur-
ther increasing the risk of rejection. On the other hand,
there is an understandable reluctance to escalate the in-
tensity of preparative regimens (and their attendant
toxicities) given that SAA is not a neoplastic disorder.
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The preparative regimens initially used for SAA
were modeled after intensive immunosuppressive
schedules used as primary treatment for this disorder
and most often included high dose cyclophospha-
mide. The addition of anti-thymocyte globulin
(ATG) to these regimens resulted in lower rates of
graft failure, at least in patients with an extensive
transfusion history, and lowered the risk of GVHD
[5]. The inclusion of cyclosporine as primary
GVHD prophylaxis likely further contributed to
lower rates of graft failure [6]. Moreover, because of
lower rates of chronic GVHD when compared to
mobilized peripheral blood, bone marrow remained
the preferred stem cell source [7]. Early studies in
transplantations from matched URDs using similar
regimens suggested an increased rate of graft failure
with the high dose cyclophosphamide and ATG com-
bination [8], leading to the incorporation of total
body irradiation (TBI), which decreased the risk of
graft rejection, albeit at a higher risk of organ toxicity
and infection [9]. Although there is no standard-of-
care preparative regimen for URD allogeneic bone
marrow transplantation (BMT) for SAA, the data
suggest that the combination of 200 mg/kg of cyclo-
phosphamide, 90 mg/kg of ATG, and 2 Gy TBI is
a reasonable choice in this setting [10]. Nonetheless,
given the significant organ toxicities of cyclophospha-
mide and the much lower extra-hematological
adverse effects of fludarabine, a protocol was devel-
oped under the auspices of the Blood and Marrow
Transplantation Clinical Trials Network (protocol
0301) to assess the safety and efficacy of substituting,
in toto or partially, fludarabine for cyclophosphamide
in this conditioning regimen.
In this edition of Biology of Blood and Marrow
Transplantation, Tolar et al. [11] describe results of
an interim analysis done on CTN protocol 0301,
which prospectively looked at the combination of
a fixed dose of fludarabine (120 mg/m2 in 4 divided
daily doses), TBI and ATG with varying total doses975
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conditioning regimen for a fully matched or 1-anti-
gen mismatched unrelated BMT for SAA, using a so-
phisticated statistical plan to determine the best dose
and guide stopping rules. This early report has been
triggered by an excess of severe adverse events on 2
dose levels and illustrates the challenges involved in
optimizing multiple-agent regimens. The authors de-
tail that 150 mg/kg of cyclophosphamide is associated
with excessive transplant-related mortality (7 deaths
of 14 patients) and suggest that the omission of cyclo-
phosphamide is associated with a higher-than-
expected graft failure rate (3 graft failures of 3
patients). Although there is little debate regarding
the former conclusion, the latter finding is less clear
because, as fate would have it, all 3 patients condi-
tioned without cyclophosphamide received cell doses
below (1 of them, 100 times less) the recommended
dose of 3  108 mononuclear cells/kg. Regardless,
the information regarding the toxicity of higher doses
of cyclophosphamide in combination with the other
agents is very relevant for the blood and marrow
transplantation field, especially because it has been
obtained in a prospective multicenter trial. Notably,
in another whim of fate, it seems that the excess
mortality was only observed after the 150 mg/kg
amount of cyclophosphamide had been selected as
the most promising dose level in the initial phase of
the study. At this time, patient accrual continues to
the 100 mg/kg and 50 mg/kg arms, now in a balanced
fashion because both dose levels seem very close to
desirability (lowest rates of graft failure and early fa-
talities).THE BOTTOM LINE
The combination of ATG (90 mg/kg), TBI (2 Gy),
fludarabine (120 mg/m2), and cyclophosphamide as
a conditioning regimen for URD BMT for SAA seems
too toxic when the total cyclophosphamide dose is
above 100 mg/kg. Fully replacing cyclophosphamide
with fludarabine may equate with too little immuno-
suppression in this setting, although this conclusion
cannot be definitive because of the low cell doses these
patients received. The final results of CTN protocol
0301, as well as of other well designed, prospectivemulticenter trials in hematopoietic stem cell transplan-
tation, are eagerly awaited.ACKNOWLEDGMENT
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